Prostate Cancer
Prostate Cancer
Advertisement
Jordana JampelmCSPC | September 11, 2024
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Read More
Karine Tawagi, MDProstate Cancer | September 10, 2024
The Two Onc Docs provide a brief overview of the the urothelial carcinoma, RCC, and prostate cancer presentations of note
Samantha Armstrong, MDProstate Cancer | September 9, 2024
Dr. Armstrong previews updates related to STAMPEDE, ARANOTE, LITESPARK-005, AMBASSADOR, and others.
Katy MarshallCRPC | September 9, 2024
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
Emily MenendezProstate Cancer | September 3, 2024
Olaparib monotherapy can provide high and durable PSA50 response rates in patients with PCa and BRCA2 alterations.
Emily MenendezCRPC | August 30, 2024
Enzalutamide was associated with improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate.
Georges Gebrael, MDmCSPC | August 27, 2024
Dr. Gebrael discusses the impact of baseline bone pain on survival outcomes in mHSPC.
Katy MarshallProstate Cancer Diagnostics | August 26, 2024
A previous study found 64Cu-SAR-bisPSMA to be safe and effective in identifying prostate cancer lesions in patients with BCR.
Katy MarshallCRPC | August 22, 2024
The study presented the results of cohorts 4 and 5 from the phase 2 KEYNOTE-199 study.
Brian Helfand, MD, PhDProstate Cancer Diagnostics | August 20, 2024
Dr. Helfand explores the potential of Clarity's 64Cu-SAR-bisPSMA agent for prostate cancer imaging.
Katy MarshallProstate Cancer Diagnostics | August 19, 2024
Black patients are often under-represented in oncology clinical trials.
Emily MenendezProstate Cancer Diagnostics | August 19, 2024
Stockholm3 is a blood-based test for the detection of prostate cancer that has demonstrated beneficial detection rates.
Adam Kinnaird, MD, PhDProstate Cancer Diagnostics | August 12, 2024
Dr. Kinnaird elaborates on some of the limitations of MRI and benefits of PET/CT staging for locoregional prostate cancer.
Brandon TwyfordAUC3 | August 8, 2024
AUC3 seeks to reshape the landscape of GU cancer management through interdisciplinary dialogue and consensus building.
Emily MenendezRLT | August 8, 2024
Multiple cycles of AcPSMA can cause side effects including salivary gland toxicity and xerostomia.
Katy MarshallmCSPC | August 6, 2024
There is a lack of research investigating associations between bone pain and OS in patients with mHSPC.
Emily MenendezCRPC | August 2, 2024
The impact of potential comorbidities and concomitant medication interactions in ARPIs are not well understood.
Brian Rini, MD, FASCOUromigos Live 2024 | August 2, 2024
Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024.
Katy MarshallLocalized | July 29, 2024
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
Katy MarshallProstate Cancer | July 26, 2024
Researchers focused on the economic impact of disparities related to insurance coverage.
Advertisement
Advertisement
Advertisement